Henry Chang

Henry has over 25 years of knowledge and experience of working in the field of HIV/AIDS in the United States (1984‐2007) and in Africa, Asia Pacific, Eastern Europe, and Latin America/Caribbean (1998-2009). Henry is the Founder & President of the Actavis Group, LLC, based in Brooklyn, New York, a consultancy company that specializes in guiding governments, corporations, institutions and NGOs to maximize the humanitarian, social, and reputational impact of their global health initiatives. Prior to establishing the Actavis Group, Henry served as Vice President of Impact Initiatives at the Global Business Coalition on HIV/AIDS, TB and malaria (GBC) from 2008 to 2009 where he was responsible in managing public-private partnerships. GBC is a coalition of 220 international companies committed to fighting the pandemics of our era through the business sector's unique skills and expertise. From 2001 to 2008, Henry was the Chief of Global Affairs at AIDS Healthcare Foundation (AHF), the largest, non-profit, HIV/AIDS medical service provider in the United States, where he was responsible in leading a global team of medical and management professionals in support of AHF’s treatment and care programs in 19 countries in Africa, Asia Pacific, and Latin America/Caribbean. During his 13 years at AHF, Henry has held various positions, including Director of Clinical Research (1996 – 1998) and member of the AHF Board of Directors (1998 – 2001). In 2003, Henry served as a technical consultant for the World Health Organization for the development of technical and operational procedures for emergency scale-up of antiretroviral treatment resource-limited settings – the “3 x5” initiative. In 1998, Henry joined DuPont Pharmaceuticals Company and served as U.S. Director of Scientific and Community Relations and was subsequently promoted to Senior Director of Business Development and Strategic Planning, Global Virology Franchise. From 1995 to 1998, Henry served as a community advisory member of numerous clinical trial protocol teams of the Adults AIDS Clinical Trials Group, National Institute of Allergy and Infectious Diseases, U.S. National Institute of Health. From 1991 to 1998, Henry served as community advisor to various pharmaceutical and biotechnology companies in the development of HIV therapeutic agents and diagnostic tools. From 1988 to 1992, Henry worked under the supervision of Dr. David Ho in the Retrovirology Laboratory at UCLA/Cedars-Sinai Medical Center as a cli